G
Gabor Kemeny
Researcher at Duke University
Publications - 17
Citations - 1256
Gabor Kemeny is an academic researcher from Duke University. The author has contributed to research in topics: Prostate cancer & Circulating tumor cell. The author has an hindex of 9, co-authored 17 publications receiving 1040 citations. Previous affiliations of Gabor Kemeny include Durham University.
Papers
More filters
Journal ArticleDOI
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.
Andrew J. Armstrong,Matthew S. Marengo,Sebastian Oltean,Sebastian Oltean,Gabor Kemeny,Rhonda L. Bitting,James D. Turnbull,Christina I. Herold,Christina I. Herold,Paul K. Marcom,Daniel J. George,Mariano A. Garcia-Blanco +11 more
TL;DR: The existence and high frequency of these C TCs coexpressing epithelial, mesenchymal, and stem cell markers in patients with progressive metastases has important implications for the application and interpretation of approved methods to detect CTCs.
Journal ArticleDOI
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
Andrew J. Armstrong,Susan Halabi,Jun Luo,David M. Nanus,Paraskevi Giannakakou,Russell Z. Szmulewitz,Daniel C. Danila,Daniel C. Danila,Patrick Healy,Monika Anand,Colin Rothwell,Julia Rasmussen,Blair Thornburg,William R. Berry,Rhonda Wilder,Changxue Lu,Yan Chen,John L. Silberstein,Gabor Kemeny,Giuseppe Galletti,Jason A. Somarelli,Santosh Gupta,Simon G. Gregory,Howard I. Scher,Howard I. Scher,Ryan Dittamore,Scott T. Tagawa,Emmanuel S. Antonarakis,Daniel J. George +28 more
TL;DR: In this article, the Androgen receptor splice variant 7 (AR-V7) results in a truncated receptor, which leads to ligand-independent constitutive activation that is not inhibited by anti-androgen therapies.
Journal ArticleDOI
Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation
Mengxi Wu,Po-Hsun Huang,Rui Zhang,Zhangming Mao,Chuyi Chen,Gabor Kemeny,Peng Li,Adrian V. Lee,Rekha Gyanchandani,Andrew J. Armstrong,Ming Dao,Subra Suresh,Tony Jun Huang +12 more
TL;DR: The development of a platform is reported that integrates acoustics and microfluidics to isolate rare CTCs from peripheral blood in high throughput while preserving their structural, biological, and functional integrity.
Journal ArticleDOI
Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.
Santosh Gupta,Jing Li,Gabor Kemeny,Rhonda L. Bitting,Joshua Beaver,Jason A. Somarelli,Kathryn E. Ware,Simon G. Gregory,Andrew J. Armstrong +8 more
TL;DR: Genomic analysis of pooled CTCs in men with mCRPC suggests a reproducible, but highly complex molecular profile that includes common aberrations in AR, ERG, c-MET, and PI3K signaling during m CRPC progression, which may be useful for predictive biomarker development.
Journal ArticleDOI
A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
Andrew J. Armstrong,Tong Shen,Susan Halabi,Gabor Kemeny,Rhonda L. Bitting,Patricia A. Kartcheske,Elizabeth Embree,Karla Morris,Carolyn Winters,Tracy A. Jaffe,Mark D. Fleming,Daniel J. George +11 more
TL;DR: Temsirolimus lacked sufficient clinical activity in men with mCRPC, despite transient CTC improvements in some men, and future studies should focus on combination approaches or novel PI3K pathway inhibitors.